AVEO Pharmaceuticals, Inc. (AVEO) Catches Eye: Stock Rises 8%

Zacks Equity Research

Tue, Dec 31, 2013, 5:15 AM

AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as the company saw its shares rise by 8% on the day. This gain can be attributable to solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend of the company as the stock is now down 17.8% in the past one-month time frame.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate has remained static. However, yesterday’s price action is encouraging, so make sure to keep a close watch on this firm in the near future.

AVEO Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

However, some better-ranked stocks in the healthcare industry include Heska Corporation (HSKA), Forest Laboratories Inc. (FRX) and Jazz Pharmaceuticals plc (JAZZ), all with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

AVEO PHARMACEUTICALS INC (AVEO): Free Stock Analysis Report

JAZZ PHARMACEUTICALS PLC IRELAND (JAZZ): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

FOREST LABS INC (FRX): Free Stock Analysis Report

Zacks Investment Research

‘Americans just work harder’ than Europeans, says CEO of Norway’s $1.6 trillion oil fund, because they have a higher ‘general level of ambition’
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
Fortune•1d ago
Warren Buffett Says 'When It Rains Gold, Put Out The Bucket' And This High Yield Investment Is Making It Rain
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...
Benzinga•19h ago
The US economy may be barrelling towards stagflation, an outcome worse than recession
As US growth shows signs of sputtering and inflation keeps rising, a re-run of the tumultuous 1970s is looking more likely.
Business Insider•10h ago
1 Unstoppable Stock That Could Join Microsoft, Apple, Nvidia, Alphabet, Amazon, and Meta in the $1 Trillion Club
The combination of artificial intelligence (AI) and cybersecurity is a match made in heaven.
Motley Fool•4h ago
If I Had to Construct a Portfolio of Just 5 ETFs, Here's Exactly What I'd Buy Right Now
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
Motley Fool•3h ago
Rooting for Trump to fail has made his stock shorters millions
Rooting for Donald Trump to fail has rarely been this profitable. Just ask a hardy band of mostly amateur Wall Street investors who have collectively made tens of millions of dollars over the past month by betting that the stock price of his social media business — Truth Social — will keep dropping despite massive buying by Trump loyalists and wild swings that often mirror the candidate’s latest polls, court trials and outbursts on Trump Social itself.
Associated Press Finance•8h ago
Investors brace for 5% Treasury yields as US inflation worries mount
As U.S. inflation worries grow, some investors are preparing for the 10-year U.S. Treasury yield to breach a 16-year high of 5% hit last October. Bond yields, which move inversely to prices, have climbed in recent weeks as signs of persistent inflation erode expectations for how deeply the Federal Reserve will be able to cut interest rates without further fueling consumer prices. Many investors are betting further weakness lies ahead for bonds.
Reuters•7h ago
1 Unstoppable Artificial Intelligence (AI) Stock to Buy and Hold Forever
This company should continue to make millionaires, just as it has over the past two decades.
Motley Fool•1h ago
AbbVie lifts profit forecast after Skyrizi sales beat expectations
(Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. Shares of AbbVie rose nearly 2.5% in premarket trading. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier.
Reuters•33m ago
Microsoft beats Q3 top and bottom lines on cloud strength
Microsoft reported better than anticipated Q3 earnings on Thursday, powered by growth in its cloud products.
Yahoo Finance•3h ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AVEO Pharmaceuticals, Inc. (AVEO) Catches Eye: Stock Rises 8%

Recommended Stories

‘Americans just work harder’ than Europeans, says CEO of Norway’s $1.6 trillion oil fund, because they have a higher ‘general level of ambition’

Warren Buffett Says 'When It Rains Gold, Put Out The Bucket' And This High Yield Investment Is Making It Rain

The US economy may be barrelling towards stagflation, an outcome worse than recession

1 Unstoppable Stock That Could Join Microsoft, Apple, Nvidia, Alphabet, Amazon, and Meta in the $1 Trillion Club

If I Had to Construct a Portfolio of Just 5 ETFs, Here's Exactly What I'd Buy Right Now

Rooting for Trump to fail has made his stock shorters millions

Investors brace for 5% Treasury yields as US inflation worries mount

1 Unstoppable Artificial Intelligence (AI) Stock to Buy and Hold Forever

AbbVie lifts profit forecast after Skyrizi sales beat expectations

Microsoft beats Q3 top and bottom lines on cloud strength